SHP2 allosteric inhibitor TK-453 alleviates psoriasis-like skin inflammation in mice via inhibition of IL-23/Th17 axis
Open accessAbstract
, which plays a significant regulatory role in cancer and inflammation-related diseases. Although SHP2 allosteric inhibitors have been used in phase I/II clinical trials for solid tumors, whether SHP2 inhibition alleviates psoriasis remains unclear. Here we expressed and purified SHP2 related proteins, and established an enzyme activity screening system for different conformations of SHP2. We launched an iterative medicinal chemistry program and identified the lead compound, TK-453. Importantly, TK-453 possessed stronger affinity with SHP2 than SHP099, evidenced by the cocrystal structure of SHP2/TK-453, revealing that the additional aryl-S-aryl bridge in TK-453 induces a 1.8 Å shift of the dichlorophenyl ring and an approximate 20° deviation of the pyrazine ring plane relative to SHP099. Furthermore, TK-453 significantly ameliorated imiquimod-triggered skin inflammation in mice via inhibition of the IL-23/Th17 axis, proving that SHP2 is a potential therapeutic target for psoriasis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These findings suggest SHP2 as a promising therapeutic target for psoriasis.
“These findings suggest SHP2 as a promising therapeutic target for psoriasis.294”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [294]
In an animal model of imiquimod (IMQ)-induced psoriasis, TK-453 demonstrated potential therapeutic effects by ameliorating macrophage inflammation in mice through the inhibition of the IL-23/Th17 axis.
“In an animal model of imiquimod (IMQ)-induced psoriasis, TK-453 demonstrated potential therapeutic effects by ameliorating macrophage inflammation in mice through the inhibition of the IL-23/Th17 axis.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [294]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · see citing works
<i>Coot</i> : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · see citing works
<i>PHENIX</i> : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · see citing works
<i>Phaser</i> crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works
<i>MolProbity</i> : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115 · see citing works
Liebschner, D. C., Afonine, P. V., Baker, M. L., Bunkòczi, G., Chen, V. B., Croll, T. I., Hintze, B. J., Hung, L., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 6,709 · see citing works
Boehncke, W., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,609 · see citing works
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M. C., Florencia, E. F., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,202 · see citing works
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,685 · see citing works
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249 · see citing works
Crystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe‐Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 996 · see citing works
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C.-C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 981 · see citing works
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · see citing works
Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509 · see citing works
The role of dendritic cells in autoimmunity
Ganguly, D., Haak, S., Sisirak, V., & Reizis, B. (2013) · Nature reviews. Immunology · doi:10.1038/nri3477 · Cited by 508 · see citing works
Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415 · see citing works
Protein tyrosine phosphatases in the JAK/STAT pathway
Xu, D. (2008) · Frontiers in bioscience · doi:10.2741/3051 · Cited by 309 · see citing works
Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor
Chen, L., Sung, S., Yip, M. L. R., Lawrence, H. R., Ren, Y., Guida, W. C., Sebti, S. M., Lawrence, N. J., & Wu, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025536 · Cited by 282 · see citing works
Molecular mechanism of SHP2 activation by PD-1 stimulation
Marasco, M., Berteotti, A., Weyershaeuser, J., Thorausch, N., Sikorska, J., Krausze, J., Brandt, H., Kirkpatrick, J., Ríos, P., Schamel, W. W. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay4458 · Cited by 268 · see citing works
Li, J., Jie, H.-B., Lei, Y. L., Gildener‐Leapman, N., Trivedi, S., Green, T., Kane, L., & Ferris, R. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1215 · Cited by 252 · see citing works
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01170 · Cited by 231 · see citing works
Self-citationShi, Z., Yu, D.-H., Park, M., Marshall, M. S., & Feng, G. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1526-1536.2000 · Cited by 228 · see citing works
Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking
Hellmuth, K., Grosskopf, S., Lum, C. T., Würtele, M., Röder, N., von Kries, J. P., Rosário, M., Rademann, J., & Birchmeier, W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710468105 · Cited by 223 · see citing works
Improvement of molecular-replacement models withSculptor
Bunkòczi, G., & Read, R. J. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910051218 · Cited by 210 · see citing works
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
Zhao, M., Guo, W., Wu, Y., Yang, C., Zhong, L., Deng, G., Zhu, Y., Liu, W., Gu, Y., Lu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.08.009 · Cited by 190 · see citing works
Self-citationTherapeutic targeting of oncogenic tyrosine phosphatases
Frankson, R., Yu, Z.-H., Bai, Y., Li, Q., Zhang, R.-Y., & Zhang, Z.-Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1510 · Cited by 189 · see citing works
Targeting Tyrosine Phosphatases: Time to End the Stigma
Stanford, S. M., & Bottini, N. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.004 · Cited by 187 · see citing works
Targeting SHP2 as a promising strategy for cancer immunotherapy
Liu, Q., Qu, J., Zhao, M., Xu, Q., & Sun, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104595 · Cited by 177 · see citing works
Self-citationHighly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis
Kim, J., & Krueger, J. G. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103905 · Cited by 175 · see citing works
Selecting protein tyrosine phosphatases as drug targets
van Huijsduijnen, R. H., Bombrun, A., & Swinnen, D. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02438-8 · Cited by 166 · see citing works
Guo, W., Liu, W., Chen, Z., Gu, Y., Peng, S., Shen, L., Shen, Y., Wang, X., Feng, G., Sun, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02351-0 · Cited by 154 · see citing works
Self-citationTyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
Song, Z., Wang, M., Yang, G., Chen, X.-P., Xu, Z., Sun, Y., & Xiong, X. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.07.010 · Cited by 137 · see citing works
Self-citationAllosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment
Xie, J., Si, X., Gu, S., Wang, M., Shen, J. H., Li, H., Shen, J. H., Li, D., Fang, Y., Liu, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01520 · Cited by 113 · see citing works
Self-citationPhosphatases start shedding their stigma of undruggability
Mullard, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.201 · Cited by 107 · see citing works
Interleukin-22 in human inflammatory diseases and viral infections
Shabgah, A. G., Navashenaq, J. G., Shabgah, O. G., Mohammadi, H., & Sahebkar, A. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.10.004 · Cited by 85 · see citing works
Grosskopf, S., Eckert, C., Arkona, C., Radetzki, S., Böhm, K., Heinemann, U., Wolber, G., von Kries, J. P., Birchmeier, W., & Rademann, J. (2015) · ChemMedChem · doi:10.1002/cmdc.201500015 · Cited by 84 · see citing works
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus
Wang, J., Mizui, M., Zeng, L., Bronson, R. T., Finnell, M. D., Terhorst, C., Kyttaris, V. C., Tsokos, G. C., Zhang, Z., & Kontaridis, M. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87037 · Cited by 74 · see citing works
Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis
Zhu, Y., Wu, Z., Yan, W., Shao, F., Ke, B., Jiang, X. L., Gao, J., Guo, W., Lai, Y., Ma, H., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114455 · Cited by 69 · see citing works
Self-citationFan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911571 · Cited by 62 · see citing works
Shao, F., Tan, T., Tan, Y., Sun, Y., Wu, X., & Xu, Q. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.06.001 · Cited by 54 · see citing works
Self-citationTargeting chondrocytes for arresting bony fusion in ankylosing spondylitis
Shao, F., Liu, Q., Zhu, Y., Fan, Z., Chen, W., Liu, S., Li, X., Guo, W., Feng, G., Yu, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26750-6 · Cited by 53 · see citing works
Self-citationTargeting SHP2 as a therapeutic strategy for inflammatory diseases
Liu, Y., Yang, X., Wang, Y., Yang, Y., Sun, D., Li, H., & Chen, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113264 · Cited by 40 · see citing works
Liu, Q., Zhai, L., Han, M., Shi, D., Sun, Z., Peng, S., Wang, M., Zhang, C., Gao, J., Yan, W., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41988 · Cited by 36 · see citing works
Self-citationSHP2-mediated mitophagy boosted by lovastatin in neuronal cells alleviates parkinsonism in mice
Liu, W., Wang, M., Shen, L., Zhu, Y., Ma, H., Liu, B., Ouyang, L., Guo, W., Xu, Q., & Sun, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00474-x · Cited by 35 · see citing works
Self-citationSong, Y., Zhao, M., Wu, Y., Yu, B., & Liu, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.021 · Cited by 34 · see citing works
Self-citationLiu, W., Yin, Y., Wang, M., Fan, T., Zhu, Y., Shen, L., Peng, S., Gao, J., Deng, G., Meng, X., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011840 · Cited by 27 · see citing works
Self-citationCheng, Y., Chiu, H., Hsiao, T.-L., Hsiao, C.-H., Lin, C., & Liao, Y. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.04.033 · Cited by 20 · see citing works
Wang, M., Lu, J., Wang, M., Yang, C., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02108 · Cited by 9 · see citing works
Self-citationPossible correlations between annular pustular psoriasis and Noonan syndrome
Catharino, A. M. D. S., Daiha, E., Carvalho, C., Martinez, D. D. A. E. S., Lima, R. B., D’Acri, A. M., Martins, C. J., & Lupi, O. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13521 · Cited by 8 · see citing works
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Pan, J., Zhou, L., Zhang, C., Xu, Q., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01038-3 · Cited by 115 · see citing works
Self-citationWang, M., Ma, X., Gao, C., Luo, Y., Fei, X., Zheng, Q., Ma, X., Kuai, L., Li, B., Wang, R., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111033 · Cited by 59 · see citing works
Self-citationZhong, L., Luo, N., Zhong, X., Xu, T., & Hao, P. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109032 · Cited by 50 · see citing works
Chen, Y., Fang, H., Chen, H., Liu, X., Zhao, J., Stanton, C., Ross, R. P., Chen, W., & Yang, B. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2464945 · Cited by 44 · see citing works
Chen, X., Chen, Y., Stanton, C., Ross, R., Zhao, J.-X., Chen, W., & Yang, B. (2023) · Nutrients · doi:10.3390/nu15081952 · Cited by 25 · see citing works
Tang, K., Wang, S., Feng, S., Yang, X., Guo, Y., Ren, X., Bai, L., Yu, B., Liu, H., & Song, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.028 · Cited by 12 · see citing works
Self-citationWu, X., Ma, Y., Wang, L., & Qin, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814390 · Cited by 12 · see citing works
An overview of small-molecule agents for the treatment of psoriasis
Jin, Z., Li, G., He, D., Chen, J., Zhang, Y., Li, M., & Yao, H. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118067 · Cited by 10 · see citing works
Purine metabolites promote ectopic new bone formation in ankylosing spondylitis
Zhang, S., Fan, Z., Ouyang, Z., Sun, H., Song, Y., Yu, H., Xu, Q., Liu, S., Sun, Y., & Shao, F. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109810 · Cited by 9 · see citing works
Self-citationSetting sail: Maneuvering SHP2 activity and its effects in cancer
Welsh, C. L., Allen, S., & Madan, L. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.003 · Cited by 8 · see citing works
Zhang, C., Cao, X., Zhao, L., Ni, Z., Du, H., Qu, J., Zhu, J., Sun, H., Sun, Y., & Ouyang, Z. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00907-z · Cited by 7 · see citing works
Self-citationTargeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy
Rehman, A. U., Zhao, C., Wu, Y., Zhu, Q., & Luo, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116201 · Cited by 7 · see citing works
SHP2: its association and roles in systemic lupus erythematosus
Yang, C., Li, R., Su, L., Lan, Y., Wang, Y.-Q., Xu, W., & Huang, A. (2023) · Inflammation Research · doi:10.1007/s00011-023-01760-w · Cited by 6 · see citing works
Chen, X., Chen, Y., Stanton, C., Ross, R. P., Zhao, J., Yang, B. K., & Chen, W. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2023.9250029 · Cited by 4 · see citing works
Protein phosphatases in systemic autoimmunity
Pan, W., Tsokos, M., Li, W., & Tsokos, G. C. (2025) · Immunometabolism · doi:10.1097/in9.0000000000000056 · Cited by 4 · see citing works
Relationship between SHP2 gene polymorphisms and systemic lupus erythematosus risk
Li, R., Zhou, L., Yang, C., Xu, W., & Huang, A. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14761 · Cited by 4 · see citing works
Song, Y., Ren, X., Yang, X., Xiong, J., Wang, W., Tang, K., & Yu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00524 · Cited by 2 · see citing works
Self-citationZhang, S., Ouyang, Z., Fan, Z., Sun, H., Yu, H., Wu, X., Sun, Y., & Shao, F. (2025) · MedComm · doi:10.1002/mco2.70310 · Cited by 2 · see citing works
Self-citationWang, S., Weng, X., Liu, C., & Cheng, B. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114986 · Cited by 2 · see citing works
- Authors
- Wang, M., Li, T., Ouyang, Z., Tang, K., Zhu, Y., Song, C., Sun, H., Yu, B., Ji, X., & Sun, Y.
- Affiliations
- State Key Laboratory of Pharmaceutical Biotechnology (CN)
- Shenzhen Polytechnic University (CN)
- Zhengzhou University (CN)
- Corresponding author
- Yu, Bin
- Ji, Xiaoyun
- Sun, Yang
- Venue
- iScience
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 25
- Issue
- 4
- Pages
- 104009
- ISSN
- 2589-0042 (ISSN-L)
- PMC
- PMC8927994
- OpenAlex
- W4214516309
- Cited by
- 20
- References
- 51
- Citations by year
- 2025: 6 · 2024: 4 · 2023: 8 · 2022: 2
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- iScience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Science and Technology Innovation Talents in Universities of Henan Province (21HASTIT045)
- Nanjing University
- National Natural Science Foundation of China (81773562, 81803081, 81871639, 81872877, 91853109)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Keywords
- SHP2, allosteric inhibitors, psoriasis, IL-23/Th17 axis, skin inflammation, SHP099, co-crystal structure, medicinal chemistry, enzyme activity screening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
